Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV-1c-SApNP vaccine
- Development stage
- Preclinical
- Lead developer
- Uvax Bio
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The RSV-1c-SApNP vaccine is an experimental nanoparticle-based vaccine candidate developed by Uvax Bio for the prevention of Respiratory Syncytial Virus (RSV) infection. The vaccine utilizes the proprietary 1c-SApNP (one-component self-assembling protein nanoparticle) platform, which is designed to display multiple copies of the RSV Fusion (F) protein in its stabilized prefusion conformation (PreF) on a protein scaffold. This multivalent display mimics the repetitive structure of a natural virus, which is intended to enhance B-cell activation and induce high titers of neutralizing antibodies. By targeting the prefusion form of the F protein—the primary target for neutralizing antibodies—the vaccine aims to provide robust protection against RSV. The project is currently in the research and discovery phase, leveraging technology originally developed at Scripps Research.
- Other names
- Uvax RSV vaccineRSV nanoparticle vaccineUvax Bio RSV vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV-1c-SApNP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV-1c-SApNP vaccine.